1-2 of 2
Matthew Schu
Close
Sort by
Journal Articles

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Clinical Trials & Observations
George Mulligan, David I. Lichter, Alessandra Di Bacco, Stephen J. Blakemore, Allison Berger, Erik Koenig, Hugues Bernard, William Trepicchio, Bin Li, Rachel Neuwirth, Nibedita Chattopadhyay, Joseph B. Bolen, Andrew J. Dorner, Helgi van de Velde, Deborah Ricci, Sundar Jagannath, James R. Berenson, Paul G. Richardson, Edward A. Stadtmauer, Robert Z. Orlowski, Sagar Lonial, Kenneth C. Anderson, Pieter Sonneveld, Jesús F. San Miguel, Dixie-Lee Esseltine, Matthew Schu
Journal: Blood
Blood (2014) 123 (5): 632–639.
https://doi.org/10.1182/blood-2013-05-504340
Published: 2014
Includes: Supplemental data
Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS
Journal: Blood
Blood (2011) 118 (21): 1377.
https://doi.org/10.1182/blood.V118.21.1377.1377
Published: 2011